Studies from Thammasat University in the Area of Psoriasis Described (The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study)
Clinical Trials Daily
2019 JUN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Research findings on Skin Diseases and Conditions - Psoriasis are discussed in a new report. According to news reporting from Pathum Thani, Thailand, by NewsRx journalists, research stated, “There are limited randomized controlled trials of oral vitamin D supplementation in psoriasis, especially in Asia, and the results are inconclusive. To investigate the clinical effect of oral vitamin D supplementation on psoriasis.”
Financial support for this research came from Thammasat University Research Fund.
The news correspondents obtained a quote from the research from Thammasat University, “Patients with psoriasis were randomized to receive vitamin D2 60,000 IU or similar-looking placebo pills once every 2 weeks for 6 months. The primary outcome was improvement of the Psoriasis Area and Severity Index (PASI) score at 3 and 6 months after treatment. Serum levels of 25(OH)D, calcium, phosphate, parathyroid hormone, and C-reactive protein and adverse events were monitored. The chi-square test, Fisher’s exact test, Student’s t-test, and Spearman’s correlation analysis were used in statistical analysis. Of 50 subjects screened, 45 were eligible and randomized to the oral vitamin D2 group (n=23) or placebo group (n=22). At enrollment, the mean PASI score was 4.45, and 26.7% of patients had vitamin D deficiency. At 3 months, the oral vitamin D2 group had significantly higher PASI improvement than the placebo group (mean PASI improvement: 1.43 versus [vs.] -0.33, p-value=0.034; mean %PASI improvement: 34.21% vs. -1.85%, p-value=0.039). The mean serum 25(OH)D level was significantly higher in the oral vitamin D group than in the placebo group (27.4 vs. 22.4 ng/mL, p-value=0.029). Serum 25(OH)D concentrations were significantly inversely correlated with PASI scores at the 6-month follow-up. No major adverse event was observed overall. Oral vitamin D2 supplementation in patients with psoriasis increased the serum vitamin D level and significantly improved the treatment outcome without increasing adverse events.”
According to the news reporters, the research concluded: “This trial is registered with Thai Clinical Trials Registry TCTR.”
For more information on this research see: The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study. Dermatology Research and Practice, 2019;2019():1-9. (Hindawi Publishing - www.hindawi.com; Dermatology Research and Practice - http://www.hindawi.com/journals/drp/)
Our news journalists report that additional information may be obtained by contacting W. Disphanurat, Dermatology Unit, Dept. of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand. Additional authors for this research include W. Viarasilpa, P. Chakkavittumrong and P. Pongcharoen.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1155/2019/5237642. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)